Literature DB >> 12805454

Antibody-dependent enhancement of Ebola virus infection.

Ayato Takada1, Heinz Feldmann, Thomas G Ksiazek, Yoshihiro Kawaoka.   

Abstract

Most strains of Ebola virus cause a rapidly fatal hemorrhagic disease in humans, yet there are still no biologic explanations that adequately account for the extreme virulence of these emerging pathogens. Here we show that Ebola Zaire virus infection in humans induces antibodies that enhance viral infectivity. Plasma or serum from convalescing patients enhanced the infection of primate kidney cells by the Zaire virus, and this enhancement was mediated by antibodies to the viral glycoprotein and by complement component C1q. Our results suggest a novel mechanism of antibody-dependent enhancement of Ebola virus infection, one that would account for the dire outcome of Ebola outbreaks in human populations.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12805454      PMCID： PMC164833          DOI： 10.1128/jvi.77.13.7539-7544.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  Antibody-dependent enhancement of viral infectivity.

Authors:  J S Porterfield
Journal:  Adv Virus Res       Date:  1986       Impact factor: 9.937

Review 2.  The pathogenesis of Ebola hemorrhagic fever.

Authors:  A Takada; Y Kawaoka
Journal:  Trends Microbiol       Date:  2001-10       Impact factor: 17.079

3.  In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.

Authors:  M L Raabe; C J Issel; R C Montelaro
Journal:  Virology       Date:  1999-07-05       Impact factor: 3.616

4.  Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody.

Authors:  H Ochiai; M Kurokawa; S Matsui; T Yamamoto; Y Kuroki; C Kishimoto; K Shiraki
Journal:  J Med Virol       Date:  1992-03       Impact factor: 2.327

5.  Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections.

Authors:  Thomas W Geisbert; Lisa E Hensley; Joan B Geisbert; Peter B Jahrling
Journal:  Virology       Date:  2002-02-01       Impact factor: 3.616

6.  Infectivity-enhancing antibodies to Ebola virus glycoprotein.

Authors:  A Takada; S Watanabe; K Okazaki; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages.

Authors:  C W Olsen; W V Corapi; C K Ngichabe; J D Baines; F W Scott
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

8.  Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

9.  Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.

Authors:  Ayato Takada; Heinz Feldmann; Ute Stroeher; Mike Bray; Shinji Watanabe; Hiroshi Ito; Martha McGregor; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody.

Authors:  S B Halstead; E J O'Rourke
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307
View more
  77 in total

Review 1.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

2.  Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Authors:  Evgeny Shmelkov; Arthur Nadas; Timothy Cardozo
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

3.  Antibody-dependent enhancement of Marburg virus infection.

Authors:  Eri Nakayama; Daisuke Tomabechi; Keita Matsuno; Noriko Kishida; Reiko Yoshida; Heinz Feldmann; Ayato Takada
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection.

Authors:  O Reynard; V Mokhonov; E Mokhonova; J Leung; A Page; M Mateo; O Pyankova; M C Georges-Courbot; H Raoul; A A Khromykh; V E Volchkov
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.

Authors:  Darryl Falzarano; Friederike Feldmann; Allen Grolla; Anders Leung; Hideki Ebihara; James E Strong; Andrea Marzi; Ayato Takada; Shane Jones; Jason Gren; Joan Geisbert; Steven M Jones; Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Authors:  Ianko D Iankov; Manoj Pandey; Mary Harvey; Guy E Griesmann; Mark J Federspiel; Stephen J Russell
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 7.  Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology.

Authors:  Lucile Warter; Ramapraba Appanna; Katja Fink
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

8.  Purification of monoclonal antibody against Ebola GP1 protein expressed in Nicotiana benthamiana.

Authors:  Andrew Fulton; Huafang Lai; Qiang Chen; Chenming Zhang
Journal:  J Chromatogr A       Date:  2015-02-11       Impact factor: 4.759

9.  An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.

Authors:  Birke Bartosch; Géraldine Verney; Marlène Dreux; Peggy Donot; Yoann Morice; François Penin; Jean-Michel Pawlotsky; Dimitri Lavillette; Francois-Loïc Cosset
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

10.  Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

Authors:  Kristina von Kietzell; Tanja Pozzuto; Regine Heilbronn; Tobias Grössl; Henry Fechner; Stefan Weger
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.